Table 3.
iStent® and iStent® inject: proportion of patients achieving target IOP levels of ≤18 mmHg or ≤21 mmHg and/or an IOP reduction of ≥20% versus baseline IOP levels
| Authors | Number of iStents implanted | % subjects with IOP ≤18 mmHg or ≤21 mmHg without ocular hypertensive medication | P-value or 95% CI | % subjects with IOP reduction ≥20% without ocular hypertensive medication | P-value or 95% CI |
|---|---|---|---|---|---|
|
iStent
| |||||
|
iStent + CE (combined procedure)
| |||||
| Samuelson et al29 | 1 | ≤21 mmHg: iStent + CE: 72% [12] ≤21 mmHg: CE alone: 50% [12] |
P<0.001 | iStent + CE: 66% [12] CE: 48% [12] |
P=0.003 |
| Craven et al30 | 1 | ≤21 mmHg: iStent + CE: 71% [24] ≤21 mmHg: CE: 61% [24] |
P=0.036 | iStent + CE: 61% [24] CE: 54% [24] |
P=0.090 |
| Arriola-Villalobos et al31 | 1 | ≤21 mmHg: iStent + CE: 42.1% [60]* ≤21 mmHg: iStent + CE: 89.5% [60]** |
na | na | na |
| Ferguson et al39 | 1 | ≤18 mmHg: iStent + CE: 52.0% [24] | na | na | na |
| Seibold et al40 | 1 | na | na | iStent + CE: 76.1% [12] | 62.4%–90.0% |
|
| |||||
| iStent (stand-alone procedure) | |||||
|
| |||||
| Katz et al36 | 1 | ≤18 mmHg: 89.2% [12] | 74.6%–97.0% | 89.2% [12] | 74.6%–97.0% |
| 2 | ≤18 mmHg: 90.2% [12] | 76.9%–97.3% | 90.2% [12] | 76.9%–97.3% | |
| 3 | ≤18 mmHg: 92.1% [12] | 78.6%–98.3% | 92.1% [12] | 78.6%–98.3% | |
| Ahmed et al37 | 2 | ≤18 mmHg: 100.0% [12]*** | na | 100.0% [12]* | na |
| Donnenfeld et al38 | 2 | ≤18 mmHg: 92.3% [12] | 79.1%–98.4% | 92.3% [12] | 79.1%–98.4% |
| ≤18 mmHg: 89.7% [36] | 72.6%–97.8% | 86.2% [36] | 68.3%–96.1% | ||
|
| |||||
| iStent inject | |||||
|
| |||||
| Voskanyan et al17 | 2 | ≤18 mmHg: 66.0% [12]* | 55%–76% | 72% [12] | 61%–81% |
| ≤18 mmHg: 81.0% [12]** | 71%–88% | 93% [12] | 86%–97% | ||
| Fea et al42 | 2 | iStent: ≤18 mmHg: 92.6%[12] | 85.3%–97.0% | iStent: 94.7%[12] | 88.0%–98.3% |
| PGA/TIM: ≤18 mmHg: 89.7%[12] | 82.0%–95.0% | PGA/TIM: 91.8[12] | 84.5%–96.4% | ||
Notes: iStent, iStent inject – Glaukos Inc., Laguna Hills, CA, USA. Numbers in square brackets indicate months of follow-up. In the studies of Arriola-Villalobos et al31 and Voskanyan et al17 the proportion of patients with IOP values of ≤18 mmHg is given separately at final visit for 38 patients regardless of patients medication:
without medication,
all patients, irrespective of medication at final visit.
In the study of Ahmed et al37 the proportion of subjects with a maximum of one medication at final visit is shown.
Abbreviations: IOP, intraocular pressure; CE, cataract extraction; PGA/TIM, fixed combination prostaglandin-analog/timolol; na., not available.